Perrigo
PRGO | NYSE
$14.13
+$0.57 (+4.20%)
At close: Sep 21, 2026, 4:00 PM ET
$14.13
$0 (0.00%)
After-hours:
Sep 21, 2026, 4:01 PM ET
Company Profile
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women’s health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Key Executives
| Name | Position |
|---|---|
| Albert Ange Manzone | Interim President, Interim CEO & Director |
| Eduardo Guarita Bezerra | Executive Vice President & Chief Financial Officer |
| Abbie Lennox | Executive Vice President & Chief Scientific Officer |
| Charles Atkinson | Executive Vice President, General Counsel & Secretary |
| David Ball | EVP and Chief Brand & Digital Officer |
| Eric S. Jacobson | Vice President of Global Investor Relations |
| Matthew Winterman | Executive Vice President of Product Supply, Operations Strategy & Transformation Officer |
| Robert Willis | Chief Human Resources Officer & Executive Vice President |
| Roberto Khoury | Executive Vice President & Chief Commercial Officer |
| Sonia Hollies | Senior VP & Treasurer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 05, 2026 | 10-Q | Quarterly Report |
| Aug 05, 2026 | 8-K | Current Report |
| Jul 29, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jul 23, 2026 | 4 | Filing |
| Jul 15, 2026 | 4 | Filing |
| Jul 15, 2026 | 4 | Filing |
| Jul 14, 2026 | 3 | Filing |
| Jul 10, 2026 | 3 | Filing |
| Jul 10, 2026 | 4 | Filing |
Perrigo
| Country | Ireland |
| IPO Date | Dec 16, 1991 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 8,100 |
| CEO | Albert A. Manzone |
Contact Details
The Sharp Building Dublin,
DU D02 TY74 Ireland
Stock Details
| Ticker Symbol | PRGO |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001585364 |
| CUSIP Number | n/a |
| ISIN Number | IE00BGH1M568 |
| SIC Code | 2834 |
Recent News
- 18 days ago / zacks.comPerrigo (PRGO) Up 13.8% Since Last Earnings Report: Can It Continue?
- 26 days ago / prnewswire.comPerrigo to Attend the Barclays Global Consumer Conference
- 27 days ago / zacks.comPRGO or NEOG: Which Is the Better Value Stock Right Now?
- 27 days ago / zacks.comShould Value Investors Buy Perrigo (PRGO) Stock?
- 1 month ago / seekingalpha.comPerrigo: The Rebound Is Just Getting Started
- 1 month ago / zacks.comPRGO vs. NEOG: Which Stock Is the Better Value Option?
- 1 month ago / zacks.comAre Investors Undervaluing Perrigo (PRGO) Right Now?
- 2 months ago / seekingalpha.comPerrigo Company plc (PRGO) Q2 2026 Earnings Call Transcript
- 2 months ago / zacks.comPerrigo (PRGO) Reports Q2 Earnings: What Key Metrics Have to Say
- 2 months ago / zacks.comPerrigo (PRGO) Surpasses Q2 Earnings and Revenue Estimates
Add to Watchlist
Select watchlists to add or remove PRGO